This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04952/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04952/identifier/drugbank/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB04952/identifier/pubchem-compound/

Statements

Subject Item
n2:DB04952
rdf:type
n3:Drug
n3:description
Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.
n3:generalReferences
# Fang X, Tiyanont K, Zhang Y, Wanner J, Boger D, Walker S: The mechanism of action of ramoplanin and enduracidin. Mol Biosyst. 2006 Jan;2(1):69-76. Epub 2005 Nov 29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16880924 # Fulco P, Wenzel RP: Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Rev Anti Infect Ther. 2006 Dec;4(6):939-45. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17181409
n3:group
investigational
n3:indication
For the treatment of bacterial infections.
owl:sameAs
n11:DB04952
dcterms:title
Ramoplanin
adms:identifier
n7:16130208 n8:604752 n9:DB04952
n3:mechanismOfAction
Ramoplanin is the first in a new class of antimicrobials to reach clinical trials. It is a glycolipodepsipeptide produced by the fermentation of <i>Actinoplanes spp.</i>. Ramoplanin blocks bacterial cell wall biosynthesis by interfering with peptidoglycan production. Ramoplanin inhibits the N-acetylglucosaminyltransferase-catalysed conversion of lipid intermediate I to lipid intermediate II, a step that occurs before the transglycosylation and transpeptidation reactions. Ramoplanin’s mechanism of action is distinct from that of glycopeptides. Unlike glycopeptides, ramoplanin does not complex with the D-Ala–D-Ala sequence of cell wall precursors.
n3:IUPAC-Name
n4:271B60D9-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B60DF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B60DE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B60DB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B60DC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B60DD-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B60D7-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B60D5-363D-11E5-9242-09173F13E4C5 n4:271B60D8-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B60D6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B60E5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B60E6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B60E0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B60E1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B60E3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B60E2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B60E4-363D-11E5-9242-09173F13E4C5
n3:absorption
No/limited absorption.
n3:affectedOrganism
Gram-positive Bacteria
n3:casRegistryNumber
76168-82-6
n3:category
n3:Bioavailability
n4:271B60EB-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B60ED-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B60EE-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B60EA-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B60E9-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B60EC-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B60DA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B60E7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B60E8-363D-11E5-9242-09173F13E4C5